Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/19/2017 06/20/2017 06/21/2017 06/22/2017 06/23/2017 Date
165.09(c) 166.29(c) 171.35(c) 173.82(c) 172.5(c) Last
3 043 884 3 857 863 5 490 814 5 745 765 8 488 878 Volume
+1.64% +0.73% +3.04% +1.44% -0.76% Change
More quotes
Financials ($)
Sales 2017 22 637 M
EBIT 2017 11 752 M
Net income 2017 8 151 M
Debt 2017 2 923 M
Yield 2017 2,62%
Sales 2018 22 773 M
EBIT 2018 11 894 M
Net income 2018 8 123 M
Finance 2018 7 298 M
Yield 2018 2,84%
P/E ratio 2017 15,61
P/E ratio 2018 15,39
EV / Sales2017 5,73x
EV / Sales2018 5,25x
Capitalization 126 856 M
More Financials
Company
Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses.The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology.Its products include... 
More about the company
Surperformance© ratings of Amgen
Trading Rating : Investor Rating :
More Ratings
Latest news on AMGEN
06/23 AMGEN : Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) Fo..
06/22 INVESTIGATORS AT AMGEN REPORT FINDIN : Regulatory...
06/22 AMGEN : Findings on Chromatography Detailed by Investigators at Amgen (Evidence ..
06/22 AMGEN : AAM Biosimilars Council Praises Unanimous Supreme Court Ruling That Will..
06/22 AMGEN : Researchers Submit Patent Application, "Process Control Systems and Meth..
06/22 AMGEN : Today's Research Reports on Stocks to Watch: Amgen and Incyte
06/21 AMGEN : To Present New Data At 22nd Congress of the European Hematology Associat..
06/19 AMGEN : FDA Accepts Amgen's Supplemental Biologics License Application To Expand..
06/15 AMGEN : New Diverticulitis Study Findings Have Been Reported from Amgen (Sequenc..
06/15 AMGEN : And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, ..
More news
Sector news : Bio Therapeutic Drugs
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on AMGEN 
04/14A biotech cash machine
2016Expectation of a turn-around
More Strategies
Latest Tweets
03:51aAmgen Receives Positive CHMP Opinion To Expand Use Of Mimpara® (cinacalcet) F.. 
12:41aNEW Blog: "Sector Update: Health Care and Biotech Stocks Hot" - by $XLV $..
12
12:02a$AMGN: Amgen announces that the Committee for Medicinal Products for Human Us.. 
06/23S&P sees mild weekly gain, Nasdaq outperforms as biotech shines $REGN $CE..
5
06/23BRIEF-Amgen receives positive CHMP opinion to expand use of mimpara  
More tweets
Qtime:136
News from SeekingAlpha
06/23 European Ad Com backs pediatric formulation of Amgen's Mimpara
06/23 Premarket analyst action - healthcare
06/22 FDA rejects Pfizer's marketing application for Epogen biosimilar
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Cantos Could Make Ilaris A Blockbuster
Advertisement
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Full-screen chart
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 181 $
Spread / Average Target 4,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN17.98%126 856
CELGENE CORPORATION16.03%104 873
GILEAD SCIENCES-1.52%92 150
REGENERON PHARMACEUTIC..43.43%54 987
VERTEX PHARMACEUTICALS83.97%33 251
ACTELION23.47%30 469
More Results